68Ga-radiolabeled AGuIX nanoparticles as dual-modality imaging agents for PET/MRI-guided radiation therapy. (July 2017)

• Record Type: Journal Article
• Authors: Bouziotis, Penelope; Stellas, Dimitris; Thomas, Eloïse; Truillet, Charles; Tsoukalas, Charalampos; Lux, François; Tsotakos, Theodoros; Xanthopoulos, Stavros; Paravatou-Petsotas, Maria; Gaitanis, Anastasios; Moulopoulos, Lia Angela; Koutoulidis, Vassilis; Anagnostopoulos, Constantinos D; Tillement, Olivier
• Is Part Of: Nanomedicine. Volume 12:Number 13(2017)
• Page Start: 1561
• Page End: 1574
• Publication Date: 2017-07
• Subjects: Gallium-68 -- PET/MR imaging -- ultrasmall AGuIX nanoparticles; Nanotechnology -- Periodicals; Medical technology -- Periodicals; Nanotechnology -- Therapeutic use -- Periodicals; 610.28
• DOI: 10.2217/nnm-2017-0032
• Languages: English
• ISSNs: 1743-5889

Abstract

Aim: The aim of this study was to develop a dual-modality positron emission tomography/magnetic resonance (PET/MR) imaging probe by radiolabeling gadolinium-containing AGuIX derivatives with the positron-emitter Gallium-68 ( 68 Ga).Materials & methods: AGuIX@NODAGA nanoparticles were labeled with 68 Ga at high efficiency. Tumor accumulation in an appropriate disease model was assessed by ex vivo biodistribution and in vivo PET/MR imaging.Results: 68 Ga-AGuIX@NODAGA was proven to passively accumulate in U87MG human glioblastoma tumor xenografts. Metabolite assessment in serum, urine and tumor samples showed that 68 Ga-AGuIX@NODAGA remains unmetabolized up to at least 60 min postinjection.Conclusion: This study demonstrates that 68 Ga-AGuIX@NODAGA can be used as a dual-modality PET/MR imaging agent with passive accumulation in the diseased area, thus showing great potential for PET/MR image-guided radiation therapy.